TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17848609
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml wine (13 g alcohol) daily for 3 months
Study: 17848609
Drug: Nonalcoholic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonalcoholic diet beer (control) daily for 3 months
Study: 11780926
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BMS-193884
Study: 15512224
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin combined with fish oil
Study: 15512224
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin only
Study: 15512224
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin combined with evening primrose oil
Study: 7884952
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg TNF‐alpha MAb
Study: 7884952
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg TNF‐alpha MAb
Study: 2229305
Drug: Pyridostigmine (PD)
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine (PD) 120 mg oral
Study: 651762
Drug: Reptilase (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reptilase (1 ml)
Study: 31862699
Drug: Oxandrolone 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 0.05 mg/kg/day (maximum dose 2.5 mg)
Study: 31150800
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.75% ropivacaine
Study: 31150800
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of 0.75% ropivacaine
Study: 31150800
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.75% ropivacaine
Study: 31150800
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml and 15 ml of 0.75% ropivacaine
Study: 28321637
Drug: Concentric-only resistance
Normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentric-only resistance training (dumbbell curls and shoulder presses, twice per week for 4 weeks)
Study: 17576783
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 mg daily)
Study: 9702848
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (bumetanide 1 mg daily and furosemide 40 mg daily)
Study: 9702848
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg daily
Study: 9606629
Drug: Dithranol (D)
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol (D) twice a day (D/D)
Study: 30633218
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (2g on both shoulders)
Study: 30633218
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point injection (2mL of 0.2% ropivacaine)
Study: 27089170
Drug: lenalidomide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenalidomide (15 mg, days 1-14) plus R-CHOP21 × 6
Study: 25006768
Drug: Socket grafting,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socket grafting, buccal overbuilding, and PTFE barrier
Study: 20398311
Drug: EcN 40
Normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcN 40 ml enema (10E8 EcN/ml)
Study: 20398311
Drug: EcN 20
Normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcN 20 ml enema (10E8 EcN/ml)
Study: 20398311
Drug: EcN 10
Normalized name: Ecnoglutide
DrugBank: Ecnoglutide (DB19019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcN 10 ml enema (10E8 EcN/ml)
Study: 18507881
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with vitamins/minerals (Pharmaton Kiddi) for 12 weeks
Study: 14581796
Drug: Low-dose erythromycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose erythromycin (5 mg/kg every 8 hours)
Study: 14581796
Drug: Low-dose erythromycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose erythromycin
Study: 10654172
Drug: Early grid
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early grid laser treatment
Study: 10654172
Drug: Delayed grid
Normalized name: MINERAL OIL 100 g in 100 mL TOPICAL LIQUID [THE GRID]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed grid laser treatment
Study: 8241496
Drug: All transretinoic
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All transretinoic acid (ATRA) combined with daunorubicin‐Ara C chemotherapy
Study: 8241496
Drug: Daunorubicin‐Ara C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin‐Ara C chemotherapy
Study: 31035469
Drug: Aquilea Colesterol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquilea Colesterol® (nutraceutical combination)
Study: 30284506
Drug: Both rTMS
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both rTMS and constraint therapy
Study: 30284506
Drug: Neither rTMS
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither rTMS nor constraint therapy (control group)
Study: 25113835
Drug: SANGUINATE 80
Normalized name: sanguinarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SANGUINATE 80 mg/kg
Study: 25113835
Drug: SANGUINATE 120
Normalized name: sanguinarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SANGUINATE 120 mg/kg
Study: 25113835
Drug: SANGUINATE 160
Normalized name: sanguinarine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SANGUINATE 160 mg/kg
Study: 19462324
Drug: GABA chocolate
Normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA chocolate (10 g with 28 mg GABA)
Study: 8355039
Drug: Ethinylestradiol (EE2)
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinylestradiol (EE2) 50 micrograms administered 24 hours before chemotherapy (FAC)
Study: 8355039
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) administered 24 hours before chemotherapy (FAC)
Study: 3320135
Drug: Zinc cream
Normalized name: CARRINGTON MOISTURE BARRIER/ZINC CREAM
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc cream BP
Study: 23486907
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg/day) plus placebo
Study: 23486907
Drug: Spironolactone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50 mg/day) plus hydrochlorothiazide (25 mg/day)
Study: 23486907
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg/day) plus placebo
Study: 23883613
Drug: Fully automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully automated closed-loop therapy (model predictive control algorithm directing insulin and 20% dextrose infusion based on FreeStyle Navigator continuous subcutaneous glucose values, n = 12)
Study: 23883613
Drug: Local protocol
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local protocol with intravenous sliding-scale insulin (n = 12)
Study: 23883613
Drug: Fully automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully automated closed-loop therapy
Study: 23883613
Drug: Local protocol
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local protocol with intravenous sliding-scale insulin
Study: 10998076
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone replacement therapy (GHRT) for 18 months
Study: 3546466
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg metaproterenol aerosol solution
Study: 3546466
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metaproterenol aerosol solution
Study: 3546466
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg metaproterenol aerosol solution
Study: 3546466
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg metaproterenol aerosol solution (repeated)
Study: 25128931
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (5 μg/min) without alpha-adrenergic blockade
Study: 25128931
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (5 μg/min) with phentolamine-induced non-selective blockade
Study: 23715032
Drug: Ketoconazole (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (600 mg)
Study: 19020163
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 1.5% mepivacaine
Study: 19020163
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 1% mepivacaine
Study: 17121036
Drug: Jingui Shenqi
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jingui Shenqi Pill plus prednisone
Study: 12936972
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/day once daily for 3 days (AZM-3)
Study: 12936972
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/day once daily for 6 days (AZM-6)
Study: 12936972
Drug: Amoxicillin-clavulanate (AMC)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (AMC) 500-125 mg three times daily for 10 days
Study: 10506596
Drug: PIXY321 (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIXY321 (375 microg/m(2) subcutaneously twice a day)
Study: 1996435
Drug: Nifedipine 5
Normalized name: nifedipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 5 mg administered sublingually
Study: 6436526
Drug: Lipid emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid emulsion (10 or 20% Intralipid) and glucose as nonprotein calories (glucose-lipid periods) with 9 g of phospholipids (PL) per day for 7 days.
Study: 6436526
Drug: Lipid emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid emulsion (10 or 20% Intralipid) and glucose as nonprotein calories (glucose-lipid periods) with 12 g of phospholipids (PL) per day for 7 days.
Study: 6436526
Drug: Glucose administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose administered alone as the sole source of nonprotein energy (glucose period).
Study: 30322353
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (4-day course)
Study: 30322353
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy (with or without steroids)
Study: 15515655
Drug: Intravenous furosemid
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemid administration
Study: 3281058
Drug: Diltiazem (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (8 mg/kg/d)
Study: 31728632
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg aerosol furosemide
Study: 16306801
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily for 4 weeks
Study: 9616531
Drug: Metacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacholine inhalation test
Study: 7630692
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of MPH
Study: 7630692
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of MPH
Study: 7630692
Drug: MPH (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPH (both doses)
Study: 31374471
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive behavioral therapy (CBT) program (UPLIFT, n = 20)
Study: 25823738
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficient (< 20 ng/mL) in SWOG cohort
Study: 25823738
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficient (< 10 ng/mL) in LYSA cohort
Study: 23555035
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) for mothers and infants, initiated at 14 weeks of pregnancy
Study: 23555035
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) for mothers and infants, initiated at 28 weeks of pregnancy (prior PMTCT recommendations)
Study: 19275278
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (10 mg/kg/day)
Study: 17067452
Drug: Dental implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implant therapy alone (Control)
Study: 11323580
Drug: Sequential ligation-sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ligation-sclerotherapy (SLS)
Study: 7965279
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg once a day
Study: 3604959
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 3% NaBr solution (1 cc per kg body weight)
Study: 3604959
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 3% NaBr solution (3 times over 6 weeks)
Study: 10369626
Drug: Antiretroviral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral agents (stavudine, lamivudine, saquinavir soft-gel capsules, nelfinavir, efavirenz)
Study: 10369626
Drug: Azithromycin, cidofovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, cidofovir, famciclovir, valacyclovir, itraconazole suspension
Study: 7771038
Drug: Automated thermo-infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated thermo-infusion dispenser with trental and actovegin for 120-hour infusion therapy
Study: 30609983
Drug: Mobile phone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone-based telemedicine system with glucometers and advice on medication, diet, and exercise
Study: 23932438
Drug: FDC solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC solifenacin 6 mg plus TOCAS 0.4 mg
Study: 23932438
Drug: FDC solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC solifenacin 9 mg plus TOCAS 0.4 mg
Study: 23932438
Drug: TOCAS 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOCAS 0.4 mg
Study: 16703972
Drug: Random urine
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random urine drug testing
Study: 8829019
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg once daily (increased to 400 mg twice daily if no improvement after 72 hours)
Study: 8829019
Drug: Trimethoprim-sulfamethoxazole 960
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole 960 mg twice daily
Study: 4046609
Drug: 3000 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 micrograms dihydrotestosterone (DHT) infusion
Study: 4046609
Drug: 3000 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 micrograms estradiol (E2) infusion
Study: 29795532
Drug: Dorsal penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal penile nerve block (DPNB) plus penile ring block (PRB) with bupivacaine injection
Study: 29795532
Drug: Dorsal penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorsal penile nerve block (DPNB) plus penile ring block (PRB) with ropivacaine injection
Study: 29795532
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without DPNB or PRB injection
Study: 26739146
Drug: Best endovascular
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best endovascular treatment (angioplasty or stenting)
Study: 22409379
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy in older patients
Study: 22409379
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy in younger patients
Study: 22409379
Drug: Drug reductions
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug reductions in older patients
Study: 22409379
Drug: Drug reductions
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug reductions in younger patients
Study: 19958075
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 or 300 mg/day
Study: 19958075
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 or 300 mg/day)
Study: 17907102
Drug: Candesartan cilexetil/hydrochlorothiazide
Normalized name: Candesartan Cilexetil/Hydrochlorothiazide 32 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexetil/hydrochlorothiazide (CC/HCTZ), 16 mg plus 12.5 mg
Study: 18544707
Drug: Troglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone treatment
Study: 10450339
Drug: Clonazepam treatment
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam treatment for 10 days
Study: 2135706
Drug: Nimodipine 30-60
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30-60 mg orally 2 hours prior to ECT
Study: 27626518
Drug: Control (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (chemotherapy without rituximab)
Study: 20386260
Drug: STEPPS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEPPS plus an adjunctive individual therapy
Study: 18353631
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy without chemotherapy
Study: 15994714
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care (tobacco use treatment delivered by mental health providers)
Study: 15994714
Drug: Usual standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual standard of care (cessation treatment delivered separately by smoking‐cessation specialists)
Study: 12623832
Drug: Dorzolamide/timolol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol combination
Study: 10100063
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine 10-40 mg/day)
Study: 6350409
Drug: Intranasal aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal aspirin (ASA) 22.5 mg per deciliter
Study: 6350409
Drug: Intranasal aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal aspirin (ASA)
Study: 6350409
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ASA, Na salicylate, and indomethacin
Study: 27756209
Drug: mDOT (mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: mDOT (mobile directly observed therapy) with fixed dose hydroxyurea (HU) therapy and standard monitoring
Study: 27756209
Drug: Standard monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard monitoring (SM) with fixed dose hydroxyurea (HU) therapy
Study: 17485707
Drug: Single autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single autologous stem-cell transplantation (ASCT) with high-dose melphalan at 200 mg/m2 (arm A)
Study: 17485707
Drug: Double autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double autologous stem-cell transplantation (ASCT) with melphalan at 200 mg/m2 followed by melphalan at 120 mg/m2 and busulfan at 12 mg/kg (arm B)
Study: 15172088
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (CE), 0.625 mg, and medroxyprogesterone acetate (MPA), 5 mg
Study: 15172088
Drug: 17beta-estradiol (E2),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-estradiol (E2), 2 mg, and norethisterone acetate (NETA), 1 mg
Study: 7911402
Drug: SCH 434
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 434 (loratadine 5 mg and pseudoephedrine sulfate 120 mg)
Study: 7911402
Drug: CTM-D (chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTM-D (chlorpheniramine maleate 12 mg and pseudoephedrine sulfate 120 mg)
Study: 28645982
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow (nHF) therapy
Study: 27928738
Drug: Vonoprazan 40
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan 40 mg
Study: 28198590
Drug: Vonoprazan 120
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan 120 mg
Study: 10079459
Drug: Self Psychological
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self Psychological Treatment (SPT)
Study: 10079459
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation Treatment (COT)
Study: 2285635
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg piretanide bid